JP7265620B2 - 強皮症の治療のための方法 - Google Patents

強皮症の治療のための方法 Download PDF

Info

Publication number
JP7265620B2
JP7265620B2 JP2021518472A JP2021518472A JP7265620B2 JP 7265620 B2 JP7265620 B2 JP 7265620B2 JP 2021518472 A JP2021518472 A JP 2021518472A JP 2021518472 A JP2021518472 A JP 2021518472A JP 7265620 B2 JP7265620 B2 JP 7265620B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
hydrate
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504181A (ja
JP2022504181A5 (enExample
Inventor
ジョン ダブリュー． アダムス，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68290393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7265620(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022504181A publication Critical patent/JP2022504181A/ja
Publication of JP2022504181A5 publication Critical patent/JP2022504181A5/ja
Priority to JP2023055658A priority Critical patent/JP2023082117A/ja
Application granted granted Critical
Publication of JP7265620B2 publication Critical patent/JP7265620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021518472A 2018-10-03 2019-10-03 強皮症の治療のための方法 Active JP7265620B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023055658A JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740855P 2018-10-03 2018-10-03
US62/740,855 2018-10-03
PCT/US2019/054576 WO2020072824A1 (en) 2018-10-03 2019-10-03 Methods for the treatment of scleroderma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023055658A Division JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Publications (3)

Publication Number Publication Date
JP2022504181A JP2022504181A (ja) 2022-01-13
JP2022504181A5 JP2022504181A5 (enExample) 2022-09-29
JP7265620B2 true JP7265620B2 (ja) 2023-04-26

Family

ID=68290393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518472A Active JP7265620B2 (ja) 2018-10-03 2019-10-03 強皮症の治療のための方法
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Country Status (5)

Country Link
US (1) US20210386706A1 (enExample)
EP (1) EP3860590B1 (enExample)
JP (2) JP7265620B2 (enExample)
ES (1) ES2951870T3 (enExample)
WO (1) WO2020072824A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2018525336A (ja) 2015-06-22 2018-09-06 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195165A4 (en) 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
AU2016205361C1 (en) * 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR20190116416A (ko) * 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020507610A (ja) * 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
AU2019280822A1 (en) * 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
AU2020206700A1 (en) * 2019-01-08 2021-07-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2018525336A (ja) 2015-06-22 2018-09-06 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Therapeutic Patents，2016年，Vol.26, No.4, pp.455-470

Also Published As

Publication number Publication date
JP2022504181A (ja) 2022-01-13
EP3860590A1 (en) 2021-08-11
WO2020072824A1 (en) 2020-04-09
EP3860590B1 (en) 2023-06-07
JP2023082117A (ja) 2023-06-13
ES2951870T3 (es) 2023-10-25
US20210386706A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
JP2023082117A (ja) 強皮症の治療のための方法
US12097182B2 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US20230149353A1 (en) Compounds and methods for treatment of primary biliary cholangitis
MX2008016133A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
US20250090514A1 (en) Method of treating cancer
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
EP2694074B1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
KR20200062240A (ko) 시포니모드의 투여 요법
WO2022093767A1 (en) Alpha-2 adrenergic receptor agonists to reduce mortality and improve outcomes in viral respiratory syndromes
HK40057784A (en) Etrasimod for use in methods for the treatment of scleroderma
HK40057784B (en) Etrasimod for use in methods for the treatment of scleroderma
JP4551649B2 (ja) 血管透過性亢進抑制剤
US20250302798A1 (en) Sting inhibitors and use thereof
HK40019900A (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
HK40019900B (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EA049014B1 (ru) Способ лечения рака

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230414

R150 Certificate of patent or registration of utility model

Ref document number: 7265620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150